The US Food and Drug Administration leveraged safety information from two other same-in-class drugs in its review of Akebia Therapeutics, Inc.’s Vafseo (vadadustat) for chronic kidney disease patients with anemia.
US FDA Review Of Akebia’s Vafseo Informed By Roxadustat, Daprodustat Safety Concerns
Vadadustat's review overlapped with two other oral HIF-PH class drugs. Safety issues with FibroGen/AstraZeneca’s roxadustat drew attention during vadadustat's first-cycle review, while GSK’s Jesduvroq labeling and postmarketing requirements informed the second-cycle approval.
